<DOC>
	<DOCNO>NCT01796093</DOCNO>
	<brief_summary>This investigator-started study . The trial cod . GC &amp; PJ-Dig-Iva2009-2012 . The author conflict interest financial sponsor The study plan accord Good Clinical Quality standard use intention-to-treat analysis . The protocol approve ethic committee . Selected patient give write informed consent . The family practitioner agree obtain collect data analysis . Analysis collect data perform single-blinded author ( without knowledge use test drug time collection data ) . Study Hypothesis : Compare effect digoxin ivabradine chronic heart failure permanent atrial fibrillation ( ischemic etiology ) . Multiple Time Frames : Primary Outcome measure medical intervention . Measurements baseline 3 month therapy ( twice , 2 different drug ) : Measurements Severity dyspnea . Digoxin serum concentration . ECG : Heart rate rest 6-min walk test . Cardiac function ( echocardiography ) : systolic function ( ejection rate , leave trial size , diastolic function . Participants follow ( ambulatory observation ) least 3 month</brief_summary>
	<brief_title>Digoxin Versus Ivabradine Heart Failure With Preserved Systolic Function</brief_title>
	<detailed_description>Selected patient chronic coronary artery disease treat percutaneous dilatation &amp; stenting and/or aortocoronary bypass . The severity myocardial ischemia induce heart failure diastolic dysfunction preserve systolic function , permanent AF . 1 Inclusion criterion : Dyspnea class III NYHA . Abnormal leave ventricular relaxation preserve ( ≥52 % ) ejection fraction ( LVEF ) . Patients either sinus rhythm permanent atrial fibrillation . 2 . Exclusion criterion : Unstable angina pectoris . Reduced systolic cardiac function ( LVEF &lt; 52 % ) . Normal diastolic function . Diabetes require insulin . Moderate severe renal hepatic dysfunction . Technically insufficient echocardiography .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Digoxin</mesh_term>
	<criteria>No need change concomitant pharmacological therapy follow month , dyspnea class III NYHA , abnormal leave ventricular relaxation preserve ( ≥52 % ) leave ventricular ejection fraction ( LVEF ) . Unstable myocardial ischemia , reduce systolic cardiac function ( LVEF &lt; 52 % ) , diabetes mellitus require insulin , moderate severe renal hepatic dysfunction , technically insufficient echocardiography .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>78 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Digoxin</keyword>
	<keyword>Ivabradine</keyword>
	<keyword>Cardiac failure</keyword>
	<keyword>Economics</keyword>
</DOC>